Trends of use and characterisation of anti-dementia drugs users: a large multinational-network population-based study

Reyes, C; Newby, D; Raventós, B; Verhamme, K; Mosseveld, M; Prieto-Alhambra, D; Burn, E; Duarte-Salles, T

Journal article

Trends of use and characterisation of anti-dementia drugs users: a large multinational-network population-based study

Abstract:: BackgroundAn updated time-trend analysis of anti-dementia drugs (ADDs) is lacking. The aim of this study is to assess the incident rate (IR) of ADD in individuals with dementia using real-world data.SettingPrimary care data (country/database) from the UK/CPRD-GOLD (2007-20), Spain/SIDIAP (2010-20) and the Netherlands/IPCI (2008-20), standardised to a common data model.MethodsCohort study. Participants: dementia patients ≥40 years old with ≥1 year of previous data. Follow-up: until the end of the study period, transfer out of the catchment area, death or incident prescription of rivastigmine, galantamine, donepezil or memantine. Other variables: age/sex, type of dementia, comorbidities. Statistics: overall and yearly age/sex IR, with 95% confidence interval, per 100,000 person-years (IR per 105 PY (95%CI)).ResultsWe identified a total of (incident anti-dementia users/dementia patients) 41,024/110,642 in UK/CPRD-GOLD, 51,667/134,927 in Spain/SIDIAP and 2,088/17,559 in the Netherlands/IPCI.In the UK, IR (per 105 PY (95%CI)) of ADD decreased from 2007 (30,829 (28,891-32,862)) to 2010 (17,793 (17,083-18,524)), then increased up to 2019 (31,601 (30,483 to 32,749)) and decrease in 2020 (24,067 (23,021-25,148)). In Spain, IR (per 105 PY (95%CI)) of ADD decreased by 72% from 2010 (51,003 (49,199-52,855)) to 2020 (14,571 (14,109-15,043)). In the Netherlands, IR (per 105 PY (95%CI)) of ADD decreased by 77% from 2009 (21,151 (14,967-29,031)) to 2020 (4763 (4176-5409)). Subjects aged ≥65-79 years and men (in the UK and the Netherlands) initiated more frequently an ADD.ConclusionsTreatment of dementia remains highly heterogeneous. Further consensus in the pharmacological management of patients living with dementia is urgently needed.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Reyes, C., Newby, D., Raventós, B., Verhamme, K., Mosseveld, M., Prieto-Alhambra, D., Burn, E., & Duarte-Salles, T. (2024). Trends of use and characterisation of anti-dementia drugs users: a large multinational-network population-based study. Age and Ageing, 53(5), afae106.

MLA Style

Reyes, C., et al. “Trends of Use and Characterisation of Anti-Dementia Drugs Users: a Large Multinational-Network Population-Based Study.” Age and Ageing, vol. 53, no. 5, Oxford University Press, 2024, p. afae106.

Chicago Style

Reyes, C, D Newby, B Raventós, K Verhamme, M Mosseveld, D Prieto-Alhambra, E Burn, and T Duarte-Salles. 2024. “Trends of Use and Characterisation of Anti-Dementia Drugs Users: a Large Multinational-Network Population-Based Study.” Age and Ageing 53 (5): afae106.
Share
Print